基于PSMA-PET/CT的前列腺癌患者放疗方案调整
这项回顾性先导研究纳入43例转诊至放疗科的前列腺癌患者,按初始计划分为根治性放疗、挽救性放疗和寡转移放疗三组。PSMA-PET/CT后60.5%(26/43)患者的初始放疗因新发现(转移和/或复发)而改变,仅39.5%(17/43)按原计划治疗。结果表明PSMA-PET/CT影响治疗决策及放疗和辅助治疗方案的选择。
要点
- PSMA-PET/CT后60.5%(26/43)患者初始放疗计划因新发现转移和/或复发而改变。
- 50%(16/32)患者的放疗计划因PSMA-PET/CT结果而改变。
- 仅39.5%(17/43)患者按初始治疗计划接受治疗。
核心结论
- PSMA-PET/CT影响前列腺癌管理中的治疗决策以及放疗和辅助治疗方案的选择。
研究设计与样本
- 回顾性先导研究,纳入43例从前列腺癌患者转诊至放疗科接受放疗的患者,18F-PSMA-PET/CT主要由放疗科医生因缺乏近期影像分期而开具。
- 患者按初始计划治疗分为三组:根治性放疗(新诊断前列腺癌)、挽救性放疗(根治性前列腺切除术后生化复发)、寡转移放疗(系统治疗后反应良好的寡转移前列腺癌)。
主要发现
- PSMA-PET/CT后,60.5%(26/43)患者的初始计划放疗因新发现(转移和/或复发)而改变。
- PSMA-PET/CT结果影响60.5%(26/43)患者的最终治疗选择,50%(16/32)患者的放疗计划因PSMA-PET/CT而改变。
- 仅39.5%(17/43)接受PSMA-PET/CT的患者按初始治疗计划接受治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer is the most common cancer among men, and its diagnosis and treatment are improving. Our study evaluated how PSMA-PET/CT prior to treatment planning might improve the optimal management of prostate cancer radiotherapy. METHODS: This retrospective pilot study included 43 prostate cancer (PCa) patients referred to our radiation oncologist department, from the urology department, for radiation therapy. 18F-PSMA-PET/CT was ordered by the radiation oncologists mainly due to the lack of resent image staging. The patients were divided into three different groups according to their initially planned treatments: radical radiation therapy (RT) (newly diagnosed PCa patients), salvage RT (patients with biochemical recurrence after radical prostatectomy), or oligometastatic RT (oligometastatic PCa patients with good response after systemic treatment). RESULTS: Following PSMA-PET/CT, the initially planned RT was changed for 60.5% of the patients due to new findings (metastases and/or recurrent disease). The final treatment choice was effected by PSMA-PET/CT outcome in 60.5% (26/43) of the patients, and in 50% (16/32) of patients, the radiation treatment plan changed following PSMA-PET/CT. Only 39.5% (17/43) of the patients who underwent PSMA-PET/CT were treated according to their initial treatment plans. CONCLUSIONS: Our results indicate that PSMA-PET/CT impacts treatment decisions and the selection of RT as well as adjuvant treatment protocols in the management of prostate cancer.
引用
- Karagiannis V, Wichmann V, Saarinen J, et al. Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT. Radiat Oncol. 2022. PMID: 35093103. doi:10.1186/s13014-022-01989-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。